<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003947</url>
  </required_header>
  <id_info>
    <org_study_id>SC-8-ATG-11-04</org_study_id>
    <nct_id>NCT05003947</nct_id>
  </id_info>
  <brief_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD</brief_title>
  <official_title>Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Foundation for Orthopaedics and Regenerative Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Foundation for Orthopaedics and Regenerative Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic&#xD;
      adult umbilical cord derived mesenchymal stem cells for the treatment of inflammatory bowel&#xD;
      disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that stem cell treatment is safe and efficacious for the treatment of&#xD;
      inflammatory bowel disease (IBD). Patients with IBD will receive a single intravenous&#xD;
      infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells. The&#xD;
      total dose will be 100 million cells. Patients will be evaluated within one month pre&#xD;
      treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>Clinical monitoring of possible adverse events or complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>Four year follow-up</time_frame>
    <description>The SIBDQ is a questionnaire to assess the physical, social, emotional, and systemic status for IBD patients. It will be completed for each follow up point.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of 100 million cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloRx</intervention_name>
    <description>cultured allogeneic adult umbilical cord derived mesenchymal stem cells</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Crohn's disease or Ulcerative Colitis&#xD;
&#xD;
          -  Understanding and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Chronic multisystem organ failure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Clinically significant Abnormalities on pre-treatment laboratory evaluation&#xD;
&#xD;
          -  Medical condition that would (based on the opinion of the investigator) compromise&#xD;
             patient's safety.&#xD;
&#xD;
          -  Continued drug abuse&#xD;
&#xD;
          -  Pre-menopausal women not using contraception&#xD;
&#xD;
          -  Previous organ transplant&#xD;
&#xD;
          -  Hypersensitivity to sulfur&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadwick Prodromos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Foundation for Orthopaedics and Regenerative Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Surgical Associates Center</name>
      <address>
        <city>St. John's</city>
        <country>Antigua and Barbuda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadwick Prodromos, M.D.</last_name>
      <phone>8476996810</phone>
      <email>research@ismoc.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Antigua and Barbuda</country>
  </location_countries>
  <reference>
    <citation>Jowett SL, Seal CJ, Barton JR, Welfare MR. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001 Oct;96(10):2921-8.</citation>
    <PMID>11693327</PMID>
  </reference>
  <reference>
    <citation>Wilcox AR, Dragnev MC, Darcey CJ, Siegel CA. A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match? Inflamm Bowel Dis. 2010 Apr;16(4):645-50. doi: 10.1002/ibd.21094.</citation>
    <PMID>19714751</PMID>
  </reference>
  <reference>
    <citation>Hu J, Zhao G, Zhang L, Qiao C, Di A, Gao H, Xu H. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med. 2016 Nov;12(5):2983-2989. Epub 2016 Sep 20.</citation>
    <PMID>27882104</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial. Gut Liver. 2018 Jan 15;12(1):73-78. doi: 10.5009/gnl17035.</citation>
    <PMID>28873511</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>stem cell treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

